Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03549117 · ClinicalTrials.gov registry record · Phase 2

A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)

A Phase 2 study of Congestion, Nasal, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
140
Enrollment target
2
Study locations

NCT03549117 is a Phase 2 study of Congestion, Nasal that has completed, run by GlaxoSmithKline. The registered enrollment target is 140 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03549117, a Phase 2 study of Congestion, Nasal, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
140 participants
Enrollment target
2
Study locations

Study Summary

This randomized, double-blind, parallel group, placebo-controlled study assessed the effects of a novel nasal dilator strip in consumers with chronic nocturnal nasal congestion who have trouble with their sleep. Participants who met the entrance criteria were suffering from nasal congestion every night or almost every night, reported trouble with their sleep and had baseline nasal openness scores at bedtime during the qualification phase of ≤ 70 on a 100-point Visual Analogue Scale (VAS) on at least four of seven qualification nights were randomized to one of two treatments for use at home. Participants returned to the study site after 7 and 14 days of nightly nasal strip use where they self-administered the validated subjective questionnaire "the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)".

Conditions Studied

Interventions

  • DEVICE Breathe Right Tan (small/medium) nasal strips
  • OTHER Placebo nasal strip

Study Locations (2)

New Jersey

  • Essex Testing Clinic, Inc - Verona

Ohio

  • Radiant Research - Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2010-10-25
Est. Completion 2011-01-14
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT03549117

The ClinicalTrials.gov registry entry for NCT03549117 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congestion, Nasal appearing as the primary indexed condition, and to 2 interventions - of which Breathe Right Tan (small/medium) nasal strips is the first listed.

NCT03549117 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Ohio.

Frequently Asked Questions

What is clinical trial NCT03549117 about?

NCT03549117 is a clinical study titled "A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)". This randomized, double-blind, parallel group, placebo-controlled study assessed the effects of a novel nasal dilator strip in consumers with chronic nocturnal nasal congestion who have trouble with their sleep. Participants who met the entrance criteria were suffering from nasal congestion every ni...

What is the current status of trial NCT03549117?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2010-10-25. Estimated completion is 2011-01-14.

What conditions does trial NCT03549117 study?

This clinical trial studies the following conditions: Congestion, Nasal.

What interventions are being tested in trial NCT03549117?

The interventions under investigation include: Breathe Right Tan (small/medium) nasal strips (DEVICE), Placebo nasal strip (OTHER).

Who is sponsoring clinical trial NCT03549117?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03549117 being conducted?

This trial has 2 study locations across New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.